Efficacy of armodafinil in moderate to severe obstructive sleep apnea patients with excessive daytime sleepiness after suboptimal usage of continuous positive airway pressure treatment: a prospective study
Sleep and Breathing · 2025
DOI: 10.1007/s11325-025-03448-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Sleep and Breathing, 2025. Verfasst von Jinjuta Ngeyvijit und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, Department of Medicine, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial …. Hauptthemen laut MEDLINE: Sleep Apnea, Obstructive, Continuous Positive Airway Pressure, Disorders of Excessive Somnolence, Benzhydryl Compounds. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Chulalongkorn University.
Abstract (Originalsprache)
PURPOSE: Armodafinil has been approved for treating excessive daytime sleepiness (EDS) in OSA patients who still experience EDS after adequately treated with CPAP. However, the effectiveness of armodafinil administration in OSA patients with suboptimal CPAP usage and persistent EDS remains unexplored. METHOD: A 12-week prospective cohort study enrolled 33 moderate to severe OSA patients with suboptimal CPAP usage (2- < 4 h/night) who experienced EDS and were naïve to armodafinil. Patients received daily 150 mg of armodafinil and continued using CPAP. Efficacy and adverse events were evaluated. RESULTS: A total of 30 patients with mean age of 45.10 ± 10.74 years and Epworth sleepiness scale (ESS) of 13.93 ± 3.16 completed the study; however, one participant completed only the 8-week follow-up. After 12 weeks, ESS was significantly decreased by 5.03 ± 4.22 (p < 0.001). Clinical global impression (CGI) rated by investigators and by participants was significantly decreased by 1.79 ± 0.72 (p < 0.001) and 1.93 ± 0.75 (p < 0.001); respectively. Pittsburgh sleep quality index (PSQI) was significantly decreased by 5.27 ± 2.93 (p < 0.001). The OSLER error index did not significantly improved (p = 0.61); however, a trend toward improvement was observed in patients with baseline psychomotor vigilance impairment (p = 0.17). While CPAP adherence showed no statistically significant change, there was a trend toward improvement from 2.99 ± 0.63 h/night at baseline to 3.47 ± 1.38 h/night (p = 0.09). No serious side effects were observed. CONCLUSION: In moderate to severe OSA patients with suboptimal CPAP usage who still experience EDS, administering armodafinil over 12 weeks period significantly improved EDS and sleep quality subjectively without compromising CPAP adherence. Armodafinil demonstrated excellent tolerability with self-limiting side effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, 1873 Rama IV Road, Pathum Wan, Bangk…
- Division of Pediatric Neurology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
- Excellence Center for Sleep Disorder, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
- Section for Mathematics, Faculty of Science and Technology, Rajamangala University of Technology Suvarnabhumi, Phranakhon Si Ayutthaya, Thailand.
- Excellence Center for Sleep Disorder, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand. narichac@hotmail.com.
ORCID-Profile: Naricha Chirakalwasan
Förderung
- Chulalongkorn University
Zitieren
APA
Ngeyvijit, J., Desudchit, T., Dadphan, N., Aswanetmanee, P., Muntham, D., & Chirakalwasan, N. (2025). Efficacy of armodafinil in moderate to severe obstructive sleep apnea patients with excessive daytime sleepiness after suboptimal usage of continuous positive airway pressure treatment: a prospective study. Sleep and Breathing. https://doi.org/10.1007/s11325-025-03448-3
Vancouver
Ngeyvijit J, Desudchit T, Dadphan N, Aswanetmanee P, Muntham D, Chirakalwasan N. Efficacy of armodafinil in moderate to severe obstructive sleep apnea patients with excessive daytime sleepiness after suboptimal usage of continuous positive airway pressure treatment: a prospective study. Sleep and Breathing. 2025. doi:10.1007/s11325-025-03448-3
BibTeX
@article{Ngeyvijit2025,
author = {Ngeyvijit, Jinjuta and Desudchit, Tayard and Dadphan, Nattapot and Aswanetmanee, Pantaree and Muntham, Dittapol and Chirakalwasan, Naricha},
title = {Efficacy of armodafinil in moderate to severe obstructive sleep apnea patients with excessive daytime sleepiness after suboptimal usage of continuous positive airway pressure treatment: a prospective study},
journal = {Sleep and Breathing},
year = {2025},
doi = {10.1007/s11325-025-03448-3}
}
EUVIMED